Fostamatinib (Tavalisse)
Revision as of 11:22, 19 April 2018 by PeterYang (talk | contribs) (PeterYang moved page Fostamatinib (R788) to Fostamatinib (Tavalisse): FDA approval)
Mechanism of action
From the NCI Drug Dictionary: An orally available disodium salt of the Syk kinase inhibitor fostamatinib with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage.
Preliminary data
Diffuse large B-cell lymphoma;Follicular lymphoma
- Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 1;115(13):2578-85. Epub 2009 Nov 17. link to original article PubMed